Altered Organization of GABA(A) Receptor mRNA Expression in the Depressed Suicide Brain.
Inter-relationships ordinarily exist between mRNA expression of GABA(A) subunits in the frontopolar cortex (FPC) of individuals that had died suddenly from causes other than suicide. However, these correlations were largely absent in persons that had died by suicide. In the present investigation, these findings were extended by examining GABA(A) receptor expression patterns (of controls and depressed individuals that died by suicide) in the orbital frontal cortex (OFC), hippocampus, amygdala. locus coeruleus (LC) and paraventricular nucleus (PVN), all of which have been implicated in either depression, anxiety or stress responsivity. Using QPCR analysis, we found that in controls the inter-relations between GABA(A) subunits varied across brain regions, being high in the hippocampus and amygdala, intermediate in the LC, and low in the OFC and PVN. The GABA(A) subunit inter-relations were markedly different in persons that died by suicide, being reduced in hippocampus and amygdala, stable in the LC, but more coordinated in the OFC and to some extent in the PVN. It seems that altered brain region-specific inhibitory signaling, stemming from altered GABA(A) subunit coordination, are associated with depression/suicide. Although, it is unknown whether GABA(A) subunit re-organization was specifically tied to depression, suicide, or the accompanying distress, these data show that the coordinated expression of this transcriptome does vary depending on brain region and is plastic.
Poulter
Michael O
MO
Molecular Brain Research Group, Department of Physiology and Pharmacology, Robarts Research Institute, University of Western Ontario London, Ontario, Canada.
Du
Lisheng
L
Zhurov
Vladimir
V
Palkovits
Miklós
M
Faludi
Gábor
G
Merali
Zul
Z
Anisman
Hymie
H
Pharmacol Rev. 1999 Sep;51(3):533-91
10471417
J Neurosci. 2004 Feb 11;24(6):1478-85
14960621
Pharmacol Ther. 2003 Jun;98(3):299-323
12782242
Biol Psychiatry. 2000 Oct 15;48(8):813-29
11063977
Arch Gen Psychiatry. 2003 Aug;60(8):804-15
12912764
Eur J Neurosci. 2004 Oct;20(8):2141-8
15450093
J Physiol. 1999 Jan 1;514 ( Pt 1):27-45
9831714
Curr Opin Pharmacol. 2002 Feb;2(1):23-33
11786305
J Neurosci. 2006 Oct 11;26(41):10387-96
17035523
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15653-8
16230605
Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):172-80
10581410
J Biol Chem. 2004 Sep 24;279(39):40451-61
15265862
Mol Psychiatry. 1996 Sep;1(4):336-42
9118360
OMICS. 2006 Winter;10(4):444-54
17233556
Mol Psychiatry. 2007 Jul;12(7):640-55
17353912
J Neurochem. 2002 Sep;82(6):1512-23
12354299
Nat Neurosci. 2004 Dec;7(12):1345-52
15558066
World J Biol Psychiatry. 2006;7(4):231-7
17071543
Crisis. 2001;22(2):66-70
11727896
Genomics. 1997 Jun 15;42(3):378-87
9205108
J Biol Chem. 2006 Oct 6;281(40):29431-5
16901909
Neuropsychologia. 2006;44(3):374-83
16112148
Pharmacol Ther. 2006 Jul;111(1):272-86
16574235
J Neurosci. 1996 Oct 15;16(20):6402-13
8815919
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12578-83
16113080
Lab Invest. 2001 Jun;81(6):913-6
11406652
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8600-5
10900018
Hum Mol Genet. 2006 Aug 15;15(16):2533-41
16835263
Biol Psychiatry. 2006 Jun 15;59(12):1116-27
16631126
Science. 2003 Jul 18;301(5631):386-9
12869766
Biotechnol Lett. 2006 Oct;28(19):1601-13
16900335
Eur J Neurosci. 2004 May;19(9):2475-87
15128401
J Neurosci. 2000 Mar 1;20(5):1735-45
10684875
Brain Res Mol Brain Res. 1997 Nov;51(1-2):212-9
9427523
J Neurochem. 2000 May;74(5):1858-69
10800928
Biol Psychiatry. 2008 Oct 15;64(8):645-52
18639864
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3107-12
12626741
J Neurochem. 1994 Apr;62(4):1643-6
8133292
Neurochem Res. 2003 Jun;28(6):965-76
12718451
J Physiol. 1996 Jun 1;493 ( Pt 2):471-84
8782110
Behav Brain Res. 2007 Aug 6;181(2):180-90
17517441
Nat Med. 1998 Oct;4(10):1166-72
9771750
CNS Neurol Disord Drug Targets. 2007 Apr;6(2):127-40
17430150
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8448-53
12034876
Eur Neuropsychopharmacol. 2006 Apr;16(3):220-3
16269239
Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39
16469371
Curr Opin Pharmacol. 2007 Feb;7(1):22-6
17055337
J Neurosci. 1999 Oct 1;19(19):8312-8
10493732
J Neurosci. 1997 Nov 1;17(21):8427-42
9334415
Pharmacol Ther. 2006 May;110(2):135-370
16522330
Pharmacol Ther. 2004 Mar;101(3):259-81
15031002
J Neurosci. 1998 Nov 15;18(22):9256-68
9801365
Arch Gen Psychiatry. 2005 May;62(5):529-35
15867106